Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT1B/1D receptors in the cat: Implications for migraine therapy

Cephalalgia

Volumn 24, Issue 2, 2004, Pages 99-109

  Boers, P M ^a,b   Donaldson, C ^a   Zagami, A S ^a   Lambert, G A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

5 HT1A receptors; 5 HT1B 1D receptors; Migraine; Naratriptan; Trigeminal nucleus caudalis

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; ELECTROSTIMULATION; MECHANICAL STIMULATION; MICROIONTOPHORESIS; MIGRAINE; NERVE STIMULATION; NONHUMAN; RECEPTIVE FIELD; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS;

ACTION POTENTIALS; ANIMALS; CATS; CEREBROVASCULAR CIRCULATION; ELECTRIC STIMULATION; INDOLES; MICROELECTRODES; MIGRAINE DISORDERS; NEURONS; PHYSICAL STIMULATION; PIPERIDINES; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRIGEMINAL CAUDAL NUCLEUS; TRYPTAMINES;

EID: 1242292335     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00636.x     Document Type: Article

References (38)

1. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15:45-68.
2. Smith R. Impact of migraine on the family. Headache 1998; 38:423-6.
3. Parry TG. The prevalence and costs of migraine in Australia. Sydney: The Centre for Applied Economic Research, UNSW. 1992.
4. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13:667-76.
5. Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and their significance in headache. Arch Surg 1940; 41:813-56.
6. Dalessio DJ. (editor) Wolff's Headache and Other Head Pain, 4th edn. New York: Oxford University Press, 1980.
7. Spira PJ, Mylecharane EJ, Lance JW. The effects of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res Clin Studies Headache 1976; 4:37-75.
8. 1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl 9:23-33.
9. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17:145-52.
10. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 1992; 597:321-30.
11. 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120:2171-7.
12. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37 Suppl 1:S15-S25.
13. Ferrari MD. Migraine. Lancet 1998; 351:1043-51.
14. 1B/1D receptors are involved in the modulation of the trigeminovascular system of the cat: a microiontophoretic study. Neuropharmacology 2000; 39:1833-47.
15. Hellier M, Boers P, Lambert GA. Fabrication of a metalcored multi-barrelled microiontophoresis assembly. J Neuroscience Meth 1990; 32:55-61.
16. Hu JW, Dostrovsky JO, Sessle BJ. Functional properties of neurons in cat trigeminal nucleus caudalis (medullary dorsal horn). I. Responses to oral-facial noxious and nonnoxious stimuli and projections to thalamus and subnucleus oralis. J Neurophysiol 1981; 45:173-92.
17. Davis KD, Dostrovsky JO. Responses of feline trigeminal spinal tract nucleus neurons to stimulation of the middle meningeal artery and sagittal sinus. J Neurophysiol 1988; 59:648-66.
18. Mandelbrod I, Feldman S, Werman R. Mediobasal hypothalamic neurons are excited by the iontophoretic application of sodium. Brain Res 1983; 273:35-44.
19. Dahlöf C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. European J Neurol 1998; 5:469-77.
20. Gobel S, Falls WM, Hockfield S. The division of the dorsal and ventral horns of the mammalian caudal medulla into eight layers using anatomical criteria. In: Anderson DJ, Matthews B, editors. Pain in the Trigeminal Region. Amsterdam: Elsevier, 1977: 443-53.
21. 1B/1D) receptors. Br J Pharmacol 1997; 122:918-22.
22. Goldstein J, Dahlöf CGH, Diener HC, Olesen J, Schellens R, Senard JM et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 1996; 16:497-502.
23. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49:1485-90.
24. 1B/D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 1997; 36:499-512.
25. 1A receptors: potential implications for prophylactic and acute therapy. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355:682-8.
26. Kempsford RD, Bailie P, Fuseau E. Oral naratriptan tablets (2.5-10 mg) exhibit dose-proportional pharmacokinetics. Cephalalgia 1997; 17:408.
27. Glaxo Wellcome Australia. Naramig tablets product information 1998.
28. 3H]S-OH-DPAT. Biogenic Amines 1997; 13:217-32.
29. 1A receptors in the rat central nervous system. J Comparative Neurol 1996; 365:289-305.
30. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain - III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987; 21:97-122.
31. 1B- immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17:833-42.
32. Martin GR. Serotonin receptor involvement in the pathogenesis and treatment of migraine. In: Goadsby PJ, Silberstein SD, editors. Headache. Boston: Butterworth-Heinemann, 1997: 25-38.
33. Pascual J, Berciano J. An open trial of buspirone in migraine prophylaxis. Preliminary report. Clin Neuropharmacol 1991; 14:245-50.
34. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987; 27:416-20.
35. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, von Schayk R et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995; 1:658-60.
36. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet 2001; 357:1016-7.
37. 1-receptor agonist naratriptan in the rat. Pain 2001; 90:227-31.
38. Bateman DN. Triptans and migraine. Lancet 2000; 355:860-1.